Hispanic Children at Higher Risk for Developing ALL

Share this content:

(ChemotherapyAdvisor) – Hispanic children are more likely than white children to inherit an ARID5B variant that increases their risk not only of developing acute lymphoblastic leukemia (ALL) but of relapse, a study reported in the Journal of Clinical Oncology online January 30.

“Recent genome-wide screens have identified genetic variations in ARID5B associated with susceptibility to childhood ALL,” Jun J. Yang, PhD, St. Jude Children's Research Hospital, Memphis, TN, and colleagues wrote. “We sought to determine the contribution of ARID5B single nucleotide polymorphisms (SNPs) to racial disparities in ALL susceptibility and treatment outcome.”

To find ARID5B variants related to ALL, the investigators compared the association between ARID5B SNP genotype and ALL susceptibility in whites (978 cases and 1,046 controls) and Hispanics (330 cases and 541 controls) and also determined the relationship between ARID5B SNP genotype and risk of ALL relapse in 1,605 children treated in two Children's Oncology Group clinical trials. Whites were defined as having a >95% European genetic ancestry; Hispanics, >10% Native American genetic ancestry (i.e., indigenous to the Americas).

Ten of the 49 ARID5B SNPs interrogated were significantly associated with ALL susceptibility in both whites and Hispanics (P<.05); 8 were associated with both ALL susceptibility and relapse hazard. “The alleles related to higher ALL incidence were always linked to poorer treatment outcome and were more frequent in Hispanics,” they noted.

Examination of ARID5B variation within different ALL treatment regimens will refine its value as a prognostic marker.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs